Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

TEVA reports in-line Q1 earnings but misses estimates for sales. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.

TEVA Matches Q1 Earnings Estimates, Lowers 2022 Sales View

Teva is one of a number of companies facing lawsuits from state and local governments seeking to hold them accountable for their alleged role in the opioid crisis.

Teva CEO Sees a Final Opioid Settlement Coming This Year

Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q1 2022 Results Conference Call May 3, 2022 8:00 AM ET Company Participants Ran Meir - Head, IR Kåre Schultz - CEO Eli Kalif - CFO Sven Dethlefs - Head, North America Commercial Conference Call Participants Balaji Prasad - Barclays David Amsellem - Piper Sandler Eric Masane - Evercore ISI Chris Schott - JPMorgan Elliot Wilbur - Raymond James Ronny Gal - Bernstein Gary Nachman - BMO Capital Markets Bhavin Patel - Bank of America Operator Good day, and thank you for standing by, and welcome to Teva's First Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Teva Pharmaceutical Industries Limited (TEVA) CEO Kåre Schultz on Q1 2022 Results - Earnings Call Transcript

Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) Q1 sales reached $3.66 billion, shrinking 8% Y/Y, missing the consensus of $3.75 billion.  The decrease is mainly due to lower revenues from generic products in North America and Copaxone, partially offset by higher revenues from.

Teva Posts Mixed Q1 Earnings, Cuts FY22 Sales Guidance Citing Copaxone Competition, Yet Shares Rise

Israel-based Teva Pharmaceutical Industries reported as expected first-quarter profit and trimmed 2022 revenue estimates due to currency fluctuations.

Teva Pharm Q1 profit down, cuts 2022 revenue outlook

Teva Pharmaceutical Industries Ltd. shares TEVA, -2.07% slid 3% in premarket trade Tuesday, after the generics company swung to a loss in the first quarter as revenue fell.

Teva shares slide 3% premarket as company swings to a loss and revenue falls

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2022. Mr. Kåre Schultz, Teva's President and CEO, said, 2022 is off to a solid start with the successful launch of a first generic version of Revlimid® in the United States, and gains in market share for AJOVY® both in the United States and in Europe, where it has solidified its leadership position as the second leading brand. AUSTEDO® continues to

Teva Reports First Quarter 2022 Financial Results

Biogen

Esperion Therapeutics

Incyte

Pfizer

Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.

Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Branded Pharmaceutical Products R&D, Inc. and Auspex Pharmaceuticals, Inc., U.S. affiliates of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), have reached an agreement with Lupin to resolve the dispute over Lupin's Abbreviated New Drug Application (“ANDA") for a generic deutetrabenazine product. Teva and Lupin have been involved in a patent infringement litigation in which Teva asserted a number of patents against Lupin

Teva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent Dispute

Etsy

Innovative Industrial Properties

A plunging market is the ideal opportunity to buy these attractively priced stocks.

3 No-Brainer Stocks to Buy With $200 During the Market Sell-Off

Walgreens

San Francisco will square off on Monday against Walgreens Boots Alliance and three other companies accused of fueling an opioid crisis in the city, the first trial to target manufacturers, distributors and pharmacies over the addictive pain medicines.

Walgreens, Teva face San Francisco trial over opioid epidemic

Investing in this generic drugmaker would be a gamble, but there are reasons why it might be worth a look.

Is Teva Pharmaceuticals a Brilliant Contrarian Pick?

Teva Pharmaceuticals (TEVA) and partner MedinCell's new drug application for risperidone to treat schizophrenia faces rejection from the FDA.

Teva's (TEVA) Schizophrenia Drug Gets CRL From the FDA

The shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) are down 3.3% at $9.84 this morning, following news that the U.S. Food and Drug Administration (FDA) sent a letter rejecting the company's marketing application for its schizophrenia treatment.

FDA Rejection Cuts Off Teva Pharmaceutical Stock's Rally

Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) U.S. affiliate and MedinCell SA (OTC: MDCLF) have received FDA Complete Response Letter (CRL) regarding TV-46000/mdc-IRM for schizophrenia. The drug candidate is risperidone extended-release injectable suspension for.

FDA Rejects Teva - MedinCell's Schizophrenia Candidate

PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and MedinCell (Euronext: MEDCL) announced that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) for the treatment of schizophrenia. Teva and Medincell remain c

Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM

Opioid settlements are a positive catalyst. Sentiment rapidly shifted from giving up to hopeful. $19 price target discussed.

3 Reasons To Buy Teva At $10

TORONTO--(BUSINESS WIRE)--Teva Canada Charts a New Prescription for Care. Share Your #PrescriptionForCare.

Teva Canada Charts a New Prescription for Care

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2022 financial results on Tuesday, May 3, 2022 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please dial the following numbers: United States 1-877-870-9135; Israel 1-809-213-985 or International +44 (0) 2071 928338; passcode: 8

Teva to Host Conference Call to Discuss First Quarter 2022 Financial Results at 8 a.m. ET on May 3, 2022

AbbVie

Johnson & Johnson

West Virginia's attorney general urged a judge to hold Johnson & Johnson (NYSE: JNJ), Teva Pharmaceuticals Industries Ltd (NYSE: TEVA), and AbbVie Inc's (NYSE: ABBV) Allergen accountable for causing a "tsunami" of opioid addiction in the.

West Virginia Says J&J, Teva, AbbVie Caused 'Tsunami' Of Opioid Addiction: Reuters

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data for two of the company's neurology portfolio treatments, AJOVY® (fremanezumab-vfrm) injection and AUSTEDO® (deutetrabenazine) tablets. These data will be presented at the American Academy of Neurology (AAN) Annual Meeting on April 2-7, 2022 in person and virtually on April 24-26, 2022. “Our commitment to improving the

Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets at 2022 American Academy of Neurology Annual Meeting

CVS Health

Florida has reached more than $878 million in settlements with CVS Health Corp (NYSE: CVS) and three drug companies to resolve claims and avert a trial next month over their roles in fueling an opioid epidemic. CVS will shell out $484 million, Teva Pharmaceutical Industries Ltd.

CVS Health, Teva Settle Florida State's Opioid-Related Claims: Report

Allergan

Endo International

Florida has reached more than $878 million of settlements with CVS Health Corp and three drug companies to resolve claims over their roles in fueling an opioid epidemic in the third most populous U.S. state.

Florida reaches $878 million opioid settlements with CVS, Teva, others

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and its affiliates, has reached an agreement with the Attorney General of Florida that settles the state's and its subdivisions opioid-related claims. The settlement will provide Florida $177 million over 15 years, as well as life-saving medicine generic Narcan® (naloxone hydrochloride nasal spray), valued at $84 million (wholesale acquisition

Teva Reaches Agreement With Florida to Settle the State's Opioid-Related Claims

Why bother buying shares of heavily indebted companies with receding revenue?

News for Teva Pharmaceutical Stock (TEVA)